• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.组蛋白去乙酰化酶抑制剂对胆管癌细胞系增殖的影响。
World J Gastroenterol. 2008 Apr 28;14(16):2578-81. doi: 10.3748/wjg.14.2578.
2
Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines.塞来昔布通过前列腺素E2途径抑制人胆管癌细胞系的增殖并诱导其凋亡。
World J Gastroenterol. 2003 Jun;9(6):1302-6. doi: 10.3748/wjg.v9.i6.1302.
3
Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.血清CYFRA 21-1在胆道癌中的作用：胆囊癌和肝内胆管癌的可靠生物标志物
Dig Dis Sci. 2015 May;60(5):1273-83. doi: 10.1007/s10620-014-3472-0. Epub 2014 Dec 9.
4
Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.组蛋白去乙酰化酶抑制剂通过抑制AKT/mTOR信号通路抑制胆囊癌细胞的增殖。
PLoS One. 2015 Aug 19;10(8):e0136193. doi: 10.1371/journal.pone.0136193. eCollection 2015.
5
Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice.c-kit受体在人胆管癌中的表达及甲磺酸伊马替尼在嵌合小鼠体内的治疗
World J Gastroenterol. 2006 Mar 14;12(10):1583-90. doi: 10.3748/wjg.v12.i10.1583.
6
Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells.组蛋白去乙酰化酶抑制剂曲古抑菌素A对人肝癌细胞的细胞生长抑制及基因表达影响
Oncology. 2004;66(6):481-91. doi: 10.1159/000079503.
7
The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.组蛋白去乙酰化酶抑制剂 PCI-24781 对 BK5.erbB2 小鼠胆囊癌的治疗作用。
J Hepatol. 2012 Jul;57(1):84-91. doi: 10.1016/j.jhep.2012.01.018. Epub 2012 Feb 9.
8
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.在异种移植肿瘤模型中，视黄酸和组蛋白脱乙酰酶抑制剂曲古抑菌素A可抑制人肾细胞癌的增殖。
Clin Cancer Res. 2005 May 1;11(9):3558-66. doi: 10.1158/1078-0432.CCR-04-1155.
9
The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.基质金属蛋白酶在肝内胆管癌、肝门部（克氏壶腹肿瘤）、肝外胆管中下段癌、胆囊癌和壶腹癌中的表达：基质金属蛋白酶在肿瘤进展和预后中的作用
Turk J Gastroenterol. 2009 Mar;20(1):41-7.
10
gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway.γ-氨基丁酸通过环磷酸腺苷依赖的蛋白激酶A/细胞外信号调节激酶1/2途径调控抑制胆管癌生长。
Cancer Res. 2005 Dec 15;65(24):11437-46. doi: 10.1158/0008-5472.CAN-05-1470.

引用本文的文献

1
HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer.组蛋白去乙酰化酶（HDAC）筛选确定I类HDAC抑制剂罗米地辛是一种有前景的用于胆管癌的表观遗传药物。
Cancers (Basel). 2021 Jul 31;13(15):3862. doi: 10.3390/cancers13153862.
2
CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.CG200745，一种组蛋白去乙酰化酶抑制剂，通过靶向 Hippo 通路的 miRNAs 诱导胆管癌细胞系产生抗肿瘤作用。
Sci Rep. 2017 Sep 7;7(1):10921. doi: 10.1038/s41598-017-11094-3.
3
The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.核受体结合SET结构域家族组蛋白赖氨酸甲基转移酶在癌症中的作用
Cold Spring Harb Perspect Med. 2017 Jun 1;7(6):a026708. doi: 10.1101/cshperspect.a026708.
4
Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.胆管癌的下一代测序研究揭示了肿瘤体细胞变异与化疗耐药性之间的关联。
Cancer. 2016 Dec 1;122(23):3657-3666. doi: 10.1002/cncr.30247. Epub 2016 Aug 6.
5
TGF-β1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4.转化生长因子-β1通过靶向组蛋白去乙酰化酶4降低miR-29a表达以促进胆管癌的致瘤性和转移。
PLoS One. 2015 Oct 6;10(10):e0136703. doi: 10.1371/journal.pone.0136703. eCollection 2015.
6
The significance of genetics for cholangiocarcinoma development.遗传学在胆管癌发生发展中的意义。
Ann Transl Med. 2013 Oct;1(3):28. doi: 10.3978/j.issn.2305-5839.2012.10.04.
7
KAT5 silencing induces apoptosis of GBC-SD cells through p38MAPK-mediated upregulation of cleaved Casp9.KAT5基因沉默通过p38丝裂原活化蛋白激酶（p38MAPK）介导的裂解型半胱天冬酶9（Casp9）上调诱导GBC-SD细胞凋亡。
Int J Clin Exp Pathol. 2013 Dec 15;7(1):80-91. eCollection 2014.
8
Sodium valproate inhibits the growth of human cholangiocarcinoma in vitro and in vivo.丙戊酸钠抑制人胆管癌细胞的体内外生长。
Gastroenterol Res Pract. 2013;2013:374593. doi: 10.1155/2013/374593. Epub 2013 Nov 13.
9
Overexpression of histone deacetylase 2 predicts unfavorable prognosis in human gallbladder carcinoma.组蛋白去乙酰化酶 2 的过表达预示着人胆囊癌的预后不良。
Pathol Oncol Res. 2013 Jul;19(3):397-403. doi: 10.1007/s12253-012-9592-y. Epub 2012 Dec 16.
10
Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.组蛋白去乙酰化酶抑制剂（SAHA）和 EZH2 的抑制作用协同抑制胆囊癌的增殖。
Cancer Sci. 2010 Feb;101(2):355-62. doi: 10.1111/j.1349-7006.2009.01387.x. Epub 2009 Oct 6.

本文引用的文献

1
Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.抑制组蛋白去乙酰化酶治疗胆道癌：一种新的有效药理学方法。
World J Gastroenterol. 2007 Sep 21;13(35):4761-70. doi: 10.3748/wjg.v13.i35.4761.
2
Epigenetic control of tumor suppression.肿瘤抑制的表观遗传调控。
Crit Rev Eukaryot Gene Expr. 2007;17(4):295-316. doi: 10.1615/critreveukargeneexpr.v17.i4.40.
3
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.组蛋白去乙酰化酶抑制剂MS-275单独使用或与硼替佐米或索拉非尼联合使用时，对人胆管癌细胞表现出强大的抗增殖作用。
World J Gastroenterol. 2007 Sep 7;13(33):4458-66. doi: 10.3748/wjg.v13.i33.4458.
4
Cancer susceptibility: epigenetic manifestation of environmental exposures.癌症易感性：环境暴露的表观遗传表现。
Cancer J. 2007 Jan-Feb;13(1):9-16. doi: 10.1097/PPO.0b013e31803c71f2.
5
Cancer as a manifestation of aberrant chromatin structure.癌症是异常染色质结构的一种表现形式。
Cancer J. 2007 Jan-Feb;13(1):3-8. doi: 10.1097/PPO.0b013e31803c5415.
6
Histone deacetylase inhibitors in cancer therapy.组蛋白去乙酰化酶抑制剂在癌症治疗中的应用
Expert Opin Investig Drugs. 2007 May;16(5):659-78. doi: 10.1517/13543784.16.5.659.
7
Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A.用组蛋白去乙酰化酶抑制剂曲古抑菌素A处理胰腺内分泌肿瘤细胞系的蛋白质组学分析。
Proteomics. 2007 May;7(10):1644-53. doi: 10.1002/pmic.200600811.
8
Development of histone deacetylase inhibitors for cancer treatment.用于癌症治疗的组蛋白去乙酰化酶抑制剂的研发。
Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. doi: 10.1586/14737140.7.4.583.
9
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.组蛋白去乙酰化酶、组蛋白去乙酰化作用与基因转录：从分子生物学到癌症治疗学
Cell Res. 2007 Mar;17(3):195-211. doi: 10.1038/sj.cr.7310149.
10
Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997-2002.1997 - 2002年美国胆囊癌、肝外胆管癌和壶腹癌的描述性研究。
Cancer Causes Control. 2007 May;18(4):415-22. doi: 10.1007/s10552-006-0109-4. Epub 2007 Jan 30.

组蛋白去乙酰化酶抑制剂对胆管癌细胞系增殖的影响。

Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.

作者信息

Xu Li-Ning, Wang Xin, Zou Sheng-Quan

机构信息

Institute of Hepatobiliary Surgery of PLA General Hospital, Beijing 100853, China.

出版信息

World J Gastroenterol. 2008 Apr 28;14(16):2578-81. doi: 10.3748/wjg.14.2578.

DOI:10.3748/wjg.14.2578
PMID:18442209
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2708373/
Abstract

AIM

To explore the effect of histone deacetylase inhibitor, trichostatin A (TSA) on the growth of biliary tract cancer cell lines (gallbladder carcinoma cell line and cholangiocarcinoma cell line) in vivo and in vitro, and to investigate the perspective of histone deacetylase inhibitor in its clinical application.

METHODS

The survival rates of gallbladder carcinoma cell line (Mz-ChA-l cell line) and cholangiocarcinoma cell lines (QBC939, KMBC and OZ cell lines) treated with various doses of TSA were detected by methylthiazoy tetrazolium (MTT) assay. A nude mouse model of transplanted gallbladder carcinoma (Mz-ChA-l cell line) was successfully established, and changes in the growth of transplanted tumor after treated with TSA were measured.

RESULTS

TSA could inhibit the proliferation of gallbladder carcinoma cell line (Mz-ChA-l cell line) and cholangiocarcinoma cell lines (QBC939, KMBC and OZ cell lines) in a dose-dependent manner. After the nude mouse model of transplanted gallbladder carcinoma (Mz-ChA-l cell line) was successfully established, the growth of cancer was inhibited in the model after treated with TSA.

CONCLUSION

TSA can inhibit the growth of cholangiocarcinoma and gallbladder carcinoma cell lines in vitro and in vivo.

摘要

目的

探讨组蛋白去乙酰化酶抑制剂曲古抑菌素A（TSA）对胆道癌细胞系（胆囊癌细胞系和胆管癌细胞系）体内外生长的影响，并研究组蛋白去乙酰化酶抑制剂在其临床应用中的前景。

方法

采用甲基噻唑基四氮唑（MTT）法检测不同剂量TSA处理的胆囊癌细胞系（Mz-ChA-1细胞系）和胆管癌细胞系（QBC939、KMBC和OZ细胞系）的存活率。成功建立了移植胆囊癌（Mz-ChA-1细胞系）裸鼠模型，并检测TSA处理后移植瘤生长的变化。

结果

TSA能以剂量依赖的方式抑制胆囊癌细胞系（Mz-ChA-1细胞系）和胆管癌细胞系（QBC939、KMBC和OZ细胞系）的增殖。成功建立移植胆囊癌（Mz-ChA-1细胞系）裸鼠模型后，TSA处理组模型中的肿瘤生长受到抑制。

结论

TSA能在体内外抑制胆管癌和胆囊癌细胞系的生长。